Diabetes drugs under scrutiny in a post-Vioxx world
暂无分享，去创建一个
The furore over Avandia (rosiglitazone), GlaxoSmithKline's blockbuster drug for diabetes, illustrates how much the US drug business has changed over the past 3 years.
[1] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.